Abstract 158P
Background
Single-cell RNA sequencing (scRNA-seq) has the ability to unveil uncommon cell populations. However, due to the high demand for tissue quality and cell viability, currently most scRNA-seq for pancreatic cancer was performed by surgical specimen or biopsy from metastatic sites. This study aims to establish a practical experience to help scientists perform primary pancreatic tumor scRNA-seq using EUS-FNB samples in real-world practice.
Methods
Two punctures from the same lesion using the same needle, without applying suction (Non-suction group) and with a negative pressure of 5 ml (Suction group) were evaluated. Single cell RNA sequencing libraries were prepared with Chromium Single cell 5’ Reagent Kits v2 (10X Genomics, USA) following the manufacturer’s protocol.
Results
A total of 20 patients were enrolled. The median age was 65.1 years old (range 46.6-83.2). Suction group achieved a cell preparation success rate of 80% (16/20) which was significantly higher than the 10% (2/20) success rate in the non-suction group (p<0.001). After the establishment of cell preparation protocol, we generate single-cell RNA transcriptomes for four patients, including two early stage (9,632 cells) and two late stage (4,592 cells). After quality control, 11,950 single cells were feasible for downstream analysis. Overall, 66% of cells (7,842) belonged to early stage and 34% (4,108) belonged to late stage. 12 major cell subtypes were identified across early and late stage. The proportion of cancer cells cluster-4 was significantly higher in late stage. Differentially expressed genes analysis showed UBE2C is the most highly expressed gene in cancer cells cluster-4. As external validation, in TCGA PAAD dataset, we found UBE2C high expression pancreatic cancer had significantly poor survival.
Conclusions
EUS-FNB with a negative pressure of 5 ml is feasible for single-cell sequencing in daily practice. A UBE2C high-expression subclone exists in early-stage pancreatic cancer and correlates with poor prognosis, potentially becoming a new therapeutic target in future studies.
Clinical trial identification
Protocol number: NCT05767697 Release date: 02 March, 2023.
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
National Health Research Institutes.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
184P - Neutropenia as a predictive and prognostic factor in nanoliposomal-irinotecan/fluorouracil/leucovorin therapy for pancreatic cancer: Findings from the NAPOLEON-2 study (NN-2301)
Presenter: Yuki Sonoda
Session: Poster Display
Resources:
Abstract
185P - Disease etiology impact on outcomes of hepatocellular carcinoma patients treated with atezolizumab plus bevacizumab: A real-world, multicenter study
Presenter: Silvia Foti
Session: Poster Display
Resources:
Abstract
186P - Efficacy and safety of fruquintinib with nab-paclitaxel in advanced G/GEJ cancer after exposure to immune checkpoint inhibitors: A single-center prospective clinical trial
Presenter: Xiaoting Ma
Session: Poster Display
Resources:
Abstract
187P - Neoadjuvant cadonilimab (PD-1/CTLA-4 bispecific antibody) plus transhepatic arterial infusion chemotherapy (HAIC) for resectable multinodular CNLC Ib/IIa hepatocellular carcinoma (Car-Hero)
Presenter: Yongguang Wei
Session: Poster Display
Resources:
Abstract
188P - Impact of metformin, statin, aspirin and insulin on the prognosis of unresectable HCC patients receiving first-line lenvatinib or atezolizumab plus bevacizumab
Presenter: Margherita Rimini
Session: Poster Display
Resources:
Abstract
189P - Safety run-in results from LEAP-014: First-line lenvatinib (len) plus pembrolizumab (pembro) and chemotherapy (chemo) for metastatic esophageal squamous cell carcinoma (ESCC)
Presenter: Shun Yamamoto
Session: Poster Display
Resources:
Abstract
190P - Perioperative camrelizumab combined with chemotherapy for locally advanced gastric or gastroesophageal junction adenocarcinoma: A single-arm, single-center, phase II clinical trial
Presenter: Jiaxing He
Session: Poster Display
Resources:
Abstract
191P - Predictive value of CXCR6 expression in gastric cancer survival and immune modulation
Presenter: Song-Hee han
Session: Poster Display
Resources:
Abstract
192P - Antiangiogenesis-related adverse events (ARAE) to predict efficacy in patients with advanced gastric cancer (AGC) treated with apatinib + chemotherapy: Results from two prospective studies
Presenter: Rongbo Lin
Session: Poster Display
Resources:
Abstract
193P - Impact of coronavirus disease 2019 on patients with unresectable hepatocellular carcinoma treated with atezolizumab/bevacizumab
Presenter: Hongjae Chon
Session: Poster Display
Resources:
Abstract